阿苯达唑替代剂型治疗泡型包虫病感染小鼠的疗效。
The efficacy of an alternative mebendazole formulation in mice infected with Echinococcus multilocularis.
机构信息
National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Key Laboratory of Parasite and Vector Biology, MOH, National Center for International Research on Tropical Diseases, WHO Collaborating Centre for Tropical Diseases, Shanghai, 200025, People's Republic of China.
Qinghai Provincial People's Hospital, Clinical Research Institute of Hydatid Disease, Xining, 810007, People's Republic of China.
出版信息
Acta Trop. 2019 Aug;196:72-75. doi: 10.1016/j.actatropica.2019.05.009. Epub 2019 May 11.
This study was conducted to investigate the efficacy of a new formulation of MBZ oily suspension (MBZ-OS) in experimentally Echinococcus multilocularis-infected mice. MBZ-OS was prepared and administered to mice infected with E. multilocularis at 12.5 and 25 mg/kg for 14 consecutive days. Then, the cysts were collected, weighed and histologically examined. The results showed that the reduction rate of cyst weight induced by MBZ-OS at two doses was 95.23% and 92.67%, which was significantly higher than that of MBZ-1% tragacanth (positive control) at corresponding concentrations (87.41% and 69.47%), indicating that the treatment of alveolar echinococcosis at lower doses could be achieved by the use of MBZ-OS. This finding shows that MBZ-OS is also a promising formulation for alveolar echinococcosis as well as cystic echinococcosis and deserves to be investigated in clinical applications against echinococcosis.
本研究旨在探讨一种新的 MBZ 油性混悬剂（MBZ-OS）在实验性泡球蚴感染小鼠中的疗效。MBZ-OS 被制备并用于感染泡球蚴的小鼠，以 12.5 和 25mg/kg 的剂量连续给药 14 天。然后收集囊泡，称重并进行组织学检查。结果表明，MBZ-OS 两个剂量组的囊泡重量减少率分别为 95.23%和 92.67%，明显高于相应浓度下的 1%黄原胶 MBZ（阳性对照）的 87.41%和 69.47%，表明使用 MBZ-OS 可以在较低剂量下治疗泡型包虫病。这一发现表明，MBZ-OS 也是一种有前途的泡球蚴制剂，也是囊型包虫病的制剂，值得在包虫病的临床应用中进行研究。
Zotero 插件